Karyopharm Therapeutics IncNASDAQ:KPTINASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7014
- TODAY'S CHANGE (%)0.0044 (0.6313%)
- Bid / Lots0.7002/ 6
- Ask / Lots0.7026/ 2
- Open / Previous Close0.7010 / 0.6970
- Day Range
- 52 Week Range
- Volume705,856
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KPTI |
|---|---|---|
| 09:32 ET | 2258 | 0.7001 |
| 09:34 ET | 500 | 0.7 |
| 09:36 ET | 3000 | 0.701 |
| 09:38 ET | 100 | 0.705 |
| 09:41 ET | 1800 | 0.7098 |
| 09:43 ET | 17319 | 0.6904 |
| 09:45 ET | 1410 | 0.6997 |
| 09:48 ET | 2417 | 0.6969 |
| 09:50 ET | 500 | 0.6938 |
| 09:52 ET | 1300 | 0.6915 |
| 09:54 ET | 387 | 0.6891 |
| 09:57 ET | 13945 | 0.6921 |
| 09:59 ET | 4608 | 0.690914 |
| 10:01 ET | 100 | 0.69056 |
| 10:03 ET | 3200 | 0.69 |
| 10:06 ET | 300 | 0.69 |
| 10:08 ET | 745 | 0.6889 |
| 10:10 ET | 1500 | 0.6897 |
| 10:12 ET | 760 | 0.6877 |
| 10:14 ET | 2392 | 0.6881 |
| 10:15 ET | 1700 | 0.6876 |
| 10:19 ET | 3268 | 0.68605 |
| 10:21 ET | 400 | 0.6825 |
| 10:24 ET | 220 | 0.68455 |
| 10:26 ET | 400 | 0.6824 |
| 10:28 ET | 1141 | 0.6816 |
| 10:30 ET | 300 | 0.6839 |
| 10:32 ET | 507 | 0.684 |
| 10:33 ET | 15372 | 0.68 |
| 10:35 ET | 2096 | 0.68315 |
| 10:37 ET | 900 | 0.6847 |
| 10:39 ET | 100 | 0.68395 |
| 10:42 ET | 3000 | 0.6839 |
| 10:44 ET | 49500 | 0.6839 |
| 10:46 ET | 598 | 0.682 |
| 10:50 ET | 11705 | 0.685 |
| 10:51 ET | 100 | 0.68715 |
| 10:53 ET | 1300 | 0.6838 |
| 10:55 ET | 282 | 0.6903 |
| 10:57 ET | 100 | 0.68695 |
| 11:00 ET | 800 | 0.6901 |
| 11:04 ET | 2300 | 0.68695 |
| 11:06 ET | 200 | 0.68695 |
| 11:11 ET | 39900 | 0.6839 |
| 11:20 ET | 700 | 0.6896 |
| 11:22 ET | 200 | 0.6867 |
| 11:24 ET | 3620 | 0.69 |
| 11:26 ET | 4560 | 0.6907 |
| 11:27 ET | 634 | 0.6907 |
| 11:31 ET | 33000 | 0.6906 |
| 11:33 ET | 7050 | 0.6909 |
| 11:36 ET | 1349 | 0.6909 |
| 11:40 ET | 2290 | 0.690899 |
| 11:42 ET | 74944 | 0.7046 |
| 11:47 ET | 19580 | 0.7046 |
| 11:54 ET | 1700 | 0.7046 |
| 11:56 ET | 600 | 0.7047 |
| 11:58 ET | 22000 | 0.7107 |
| 12:02 ET | 47396 | 0.7092 |
| 12:03 ET | 9868 | 0.7082 |
| 12:05 ET | 1300 | 0.7082 |
| 12:07 ET | 100 | 0.7101 |
| 12:09 ET | 272 | 0.7102 |
| 12:12 ET | 6200 | 0.7084 |
| 12:14 ET | 1819 | 0.7081 |
| 12:16 ET | 2000 | 0.706792 |
| 12:21 ET | 513 | 0.7015 |
| 12:25 ET | 6570 | 0.7015 |
| 12:27 ET | 629 | 0.7014 |
| 12:30 ET | 100 | 0.7008 |
| 12:36 ET | 19425 | 0.701 |
| 12:38 ET | 2144 | 0.7004 |
| 12:39 ET | 2100 | 0.7006 |
| 12:41 ET | 300 | 0.7043 |
| 12:43 ET | 100 | 0.7006 |
| 12:48 ET | 101611 | 0.7082 |
| 12:50 ET | 3100 | 0.7028 |
| 12:52 ET | 61438 | 0.7092 |
| 12:56 ET | 2504 | 0.7092 |
| 12:57 ET | 500 | 0.7092 |
| 12:59 ET | 5000 | 0.709301 |
| 01:01 ET | 200 | 0.7051 |
| 01:03 ET | 400 | 0.701 |
| 01:06 ET | 100 | 0.701 |
| 01:10 ET | 100 | 0.70305 |
| 01:14 ET | 250 | 0.701 |
| 01:15 ET | 200 | 0.70305 |
| 01:17 ET | 5455 | 0.7021 |
| 01:19 ET | 600 | 0.7021 |
| 01:21 ET | 100 | 0.7012 |
| 01:24 ET | 4131 | 0.7001 |
| 01:26 ET | 100 | 0.7001 |
| 01:28 ET | 500 | 0.7015 |
| 01:30 ET | 2600 | 0.7001 |
| 01:32 ET | 1000 | 0.7028 |
| 01:35 ET | 37821 | 0.7015 |
| 01:37 ET | 200 | 0.7014 |
| 01:39 ET | 505 | 0.7026 |
| 01:44 ET | 100 | 0.7014 |
Sep 3, 2024
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Tuesday Sep 03, 2024 by Dow Jones
4:05PM ET on Tuesday Sep 03, 2024 by Dow JonesKaryopharm to Participate at Upcoming Investor Conferences, from 7:00AM ET on Tuesday Sep 03, 2024 by Dow Jones
7:00AM ET on Tuesday Sep 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Karyopharm Therapeutics Inc | 86.9M | -0.8x | --- |
FibroGen Inc | 37.4M | -0.2x | --- |
Agenus Inc | 108.5M | -0.4x | --- |
Seres Therapeutics Inc | 139.5M | -0.7x | --- |
Sutro Biopharma Inc | 272.1M | -1.9x | --- |
Kamada Ltd | 304.7M | 18.1x | -22.48% |
Company Information
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.
Contact Information
- Headquarters
- 85 Wells Avenue, Second FloorNEWTON, MA, United States 02459
- Phone
- 617-658-0600
- Fax
- 302-655-5049
Executives
- President, Chief Executive Officer, Director
- Richard Paulson
- Chief Financial Officer, Executive Vice President, Treasurer
- Michael Mason
- Executive Vice President, Chief Commercial Officer
- Sohanya Cheng
- Executive Vice President, Chief Development Officer
- Stuart Poulton
- Executive Vice President, Chief Medical Officer
- Reshma Rangwala
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $86.9M |
|---|---|
Revenue (TTM) | $145.7M |
Shares Outstanding | 124.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.19 |
EPS | $-0.84 |
Book Value | $-1.19 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 0.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -59.21% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
